Studies closed to recruitment

Links to studies that have closed to recruitment can be found below. Click on the study title for further details:

Study titleDate closed to recruitmentCurrent status
BioMOx BioMOx: The Oxford Study for Biomarkers in Motor Neuron Disease2018-12-31• Data being analysed;
• Manuscript in preparation;
• Results published (links to papers provided).
Tongue EIM Developing electrical impedance myography of the tongue for motor system disorders2018-07-31Closed to Recruitment, In Follow Up
Biogen Methodology study Methodology Study of Novel Outcome Measures to Assess Progression of ALS2017-05-31Analysis
ALS/FTD study Is ALS/FTD Neuropsychologically distinct from FTD?2017-10-15Closed to Recruitment, No Follow Up
CALL-Me Assessment of care augmentation by location-linked messaging in amyotrophic lateral sclerosis with respiratory impairment compared with current standard care2019-02-07Closed to Recruitment, In Follow Up
OPTCARE Neuro Evaluation of the clinical and cost­ effectiveness of Short-­term Integrated Palliative Care Services (SIPC) to OPTimise CARE for people with advanced long­term Neurological conditions (OPTCARE Neuro)2017-11-10Closed to Recruitment, In Follow Up
ALSCarE A Programme for ALS Care in Europe (ALSCarE)2017-08-04Closed to Recruitment, In Follow Up
EncoreAnywhere Monitoring and promoting adherence to non-invasive ventilation in motor neurone disease using EncoreAnywhere telemonitoring2017-04-01Closed to Recruitment, In Follow Up
CSNAT Enabling tailored and coordinated support for family carers of people with Motor Neurone Disease (MND) through adaptation of a Carer Support Needs Assessment Tool (CSNAT) Intervention2019-06-17Closed to Recruitment, no follow up
COMMEND feasibility study A feasibility study of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND)2018-11-30Closed to Recruitment, In Follow Up
Using MRI to investigate energy metabolism Using MRI to investigate energy metabolismClosed to Recruitment, no follow up
MIROCALS Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, placebo- controlled, phase-II Proof of Concept/ Proof of Mechanism Clinical Trial2019-11-04Closed to Recruitment, In Follow Up